Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wubi Shanyao Pill is a Traditional Chinese Medicine (TCM) herbal formula traditionally used to treat kidney-related conditions, particularly those characterized by spleen and kidney deficiency. The formula typically comprises several botanical ingredients, including *Dioscorea opposita* (Shanyao), *Rehmannia glutinosa*, *Cistanche deserticola*, *Cuscuta chinensis*, *Poria cocos*, *Achyranthes bidentata*, and *Alisma plantago-aquatica*. In modern clinical research, it is being investigated for its potential to reduce proteinuria and slow the progression of kidney failure in patients with IgA nephropathy who are at moderate to high risk of renal decline. The formula is thought to exert its therapeutic effects through multi-target mechanisms involving immunomodulation and anti-inflammatory pathways, although specific molecular targets for the entire combination are not fully defined in a Western pharmacological context.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on wubi shanyao pill.